Dr Danilo Moriel Gomes
Glaxo SmithKline, Italy

Over the past 15 years, Dr. Moriel has played a crucial role in the evolution of modern vaccinology by designing innovative approaches based on proteomic, reverse and structural vaccinology strategies. These strategies provided key milestones for the development of broadly protective vaccines against several important human pathogens including pathogenic E. coli, non-typeable H. influenzae and A. baumannii. His findings has also increased the understanding of the functional, structural and regulatory mechanisms behind the most relevant vaccine targets and virulence factors of these pathogens. In 2015, Dr. Moriel joined the GSK Vaccines Institute for Global Health (GVGH) as Head of Molecular Biology to drive the generation of new vaccine platforms and the construction of Shigella multicomponent vaccine’s production strains. After completion, Shigella vaccine entered clinical development and Dr. Moriel was appointed as Strep A vaccine Project Leader in 2017.

LinkedIn: https://www.linkedin.com/in/danilomoriel/